Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2003-11-20
2009-10-06
Pryor, Alton N (Department: 1616)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07598252
ABSTRACT:
This invention pertains to compounds which specifically inhibit the adenosine A1receptor and the use of these compounds to treat a disease associated with A1adenosine receptors in a subject.
REFERENCES:
patent: 3037980 (1962-06-01), Hitchings et al.
patent: 3910913 (1975-10-01), Kim et al.
patent: 5208240 (1993-05-01), Peet et al.
patent: 5296484 (1994-03-01), Coghlan et al.
patent: 5409930 (1995-04-01), Spada et al.
patent: 5516894 (1996-05-01), Reppert
patent: 5580870 (1996-12-01), Barker et al.
patent: 5639913 (1997-06-01), Lidor et al.
patent: 5646130 (1997-07-01), Shi
patent: 5646156 (1997-07-01), Jacobson et al.
patent: 5681941 (1997-10-01), Cook et al.
patent: 5710158 (1998-01-01), Myers et al.
patent: 5714493 (1998-02-01), Myers et al.
patent: 5721237 (1998-02-01), Myers et al.
patent: 5747498 (1998-05-01), Schnur et al.
patent: 5780450 (1998-07-01), Shade et al.
patent: 5780481 (1998-07-01), Jacobson et al.
patent: 5834609 (1998-11-01), Horne et al.
patent: 5877180 (1999-03-01), Linden et al.
patent: 5877218 (1999-03-01), Herzig et al.
patent: 5877221 (1999-03-01), Cohen et al.
patent: 5880159 (1999-03-01), Herzig et al.
patent: 5889026 (1999-03-01), Alanine et al.
patent: 5914349 (1999-06-01), Cohen et al.
patent: 5935964 (1999-08-01), Baraldi et al.
patent: 5962458 (1999-10-01), Lohmann et al.
patent: 5994408 (1999-11-01), Cohen et al.
patent: 6103899 (2000-08-01), Horne et al.
patent: 6117878 (2000-09-01), Linden
patent: 6465456 (2002-10-01), Springer et al.
patent: 6664252 (2003-12-01), Castelhano et al.
patent: 6916804 (2005-07-01), Castelhano et al.
patent: 7202252 (2007-04-01), Wilson et al.
patent: 2002/0028782 (2002-03-01), Castelhano et al.
patent: 2002/0058667 (2002-05-01), Castelhano et al.
patent: 2002/0094974 (2002-07-01), Castelhano et al.
patent: 2003/0036545 (2003-02-01), Castelhano et al.
patent: 2003/0045536 (2003-03-01), Castelhano et al.
patent: 2003/0073708 (2003-04-01), Castelhano et al.
patent: 2003/0139427 (2003-07-01), Castelhano et al.
patent: 2003/0229067 (2003-12-01), Castelhano et al.
patent: 2004/0082599 (2004-04-01), Castelhano et al.
patent: 2005/0043332 (2005-02-01), Castelhano et al.
patent: 2005/0119271 (2005-06-01), Castelhano et al.
patent: 2008/0070936 (2008-03-01), Castelhano et al.
patent: 3145287 (1993-05-01), None
patent: 0322242 (1989-06-01), None
patent: 0514540 (1992-11-01), None
patent: 0682027 (1995-11-01), None
patent: 0729758 (1996-09-01), None
patent: 0773023 (1997-05-01), None
patent: 1246623 (2006-08-01), None
patent: 0915303 (1963-01-01), None
patent: 0157280 (1986-02-01), None
patent: 09291089 (1999-05-01), None
patent: WO 9320078 (1993-10-01), None
patent: WO 9413676 (1994-06-01), None
patent: WO 9417090 (1994-08-01), None
patent: WO 9419349 (1994-09-01), None
patent: WO 9424136 (1994-10-01), None
patent: WO 9511681 (1995-05-01), None
patent: WO 9518617 (1995-07-01), None
patent: WO 9519774 (1995-07-01), None
patent: WO 9519970 (1995-07-01), None
patent: WO 9520597 (1995-08-01), None
patent: WO 9619478 (1996-06-01), None
patent: WO 9702266 (1997-01-01), None
patent: WO 9705138 (1997-02-01), None
patent: WO 9733879 (1997-09-01), None
patent: 9747601 (1997-12-01), None
patent: WO 9807726 (1998-02-01), None
patent: WO 9808382 (1998-03-01), None
patent: WO 9822465 (1998-05-01), None
patent: WO 9829397 (1998-07-01), None
patent: WO 9857651 (1998-12-01), None
patent: 9908460 (1999-02-01), None
patent: WO 9906053 (1999-02-01), None
patent: WO 9933815 (1999-07-01), None
patent: WO 9942093 (1999-08-01), None
patent: 9964407 (1999-12-01), None
patent: WO 9962518 (1999-12-01), None
patent: 0003741 (2000-01-01), None
patent: WO 0139777 (2001-06-01), None
patent: WO 02057267 (2002-07-01), None
patent: WO 03048120 (2003-06-01), None
patent: 03053361 (2003-07-01), None
patent: 03053366 (2003-07-01), None
Nyce & Metzger, DNA antisense Therapy for Asthma in an Animal Model, Nature, 1977, 385, 721-725.
Abbracchio M., et al., (1999) “Brain Adenosine Receptors as Targets for Therapeutic Intervention in Neurodegenerative Diseases”, Ann, NY,Acad. Sci,890: 79-92.
Banker, G.S. et al.,Modern Pharmaceutics, 3rded., Marcel Dekker, New York, 1996, p. 596.
Barrett, R.J. (1996) “Realizing the Potential of Adenosine-Receptor-Based Therapeutics”Proc. West. Pharmacol. Soc. 39: 61-66.
Barrett, R.J. et al., “N-0861 selectively antagonizes adenosine A1 receptors in vivo”European J. Pharmacology(1992) 216:9-16.
Brand A., et al., (2001) “Adenosine A1 and A3 receptors mediate inhibition of synaptic transmission in rat cortical neurons”,Neuropharmacology, 40: 85-95.
Bundy, G.L. et al. (1995) “Synthesis of Novel 2,4-Diaminopyrrolo-[2,3-d]pyrimidines with Antioxidant, Neuroprotective, and Antiasthma Activity”J. Med. Chem. 38: 4161-4163.
Campbell, R.M. et al., “Selective A1—Adenosine Receptor Antagonists Identified Using YeastSaccharomyces cerevisiaeFunctional Assays”Bioorg.&Med. Chem. Lett.(1999) 9(16): 2413-2418.
Chen, Y. L., et al., “Synthesis and Oral Efficacy of a 4-(Butylethylamino)pyrrolo[2,3-d]pyrimidine: A Centrally Active Corticotropin-Releasing Factor1Receptor Antagonist”, (1997)J. Med. Chem.,40: 1749-1754.
Cummings, J. et al., “Antagonism of the Cardiodepressant Effects of Adenosine during Acute Hypoxia”Academic Emergency Medicine(2000), 7(8): 618-624.
DeNinno, M.P. inAnnual Reports in Medicinal Chemistry, vol. 33, (Academic Press: San Diego, 1998), pp. 111-120.
Dhainaut, A. et al., “New Purines and Purine Analogs as Modulators of Multidrug Resistance”J. Med. Chem. (1996) 39: 4099-4108.
Dooley, M.J. et al., “Theoretical Structure-Activity Studies of Adenosine A1 Ligands: Requirements for Receptor Affinity”Bioorg. Med. Chem.(1996), 4(6): 923-934.
Feoktistove, I. et al., (1998) “Adenosine A2Breceptors: a novel therapeutic target in asthma?”,TiPS19: 148-153.
Gao, E. et al., “Adenosine A1 Receptor Antagonist Prolongs Survival in the Hypoxic Rat”J. Cardiovascular Pharm.(2001) 38: 384-394.
Iwamura, H. et al. (1996) “Quantitative Aspects of the Receptor Binding of Cytokinin Agonists and Antagonists”J. Med. Chem., 26: 838-844.
Jacobson K.A., et al., (1998) “Adenosine A3 receptors: novel ligands and paradoxical effects”,TiPS19:184-191.
Jacobson K.A., et al., (1997) “Pharmacological Characterization of Novel A3 Adenosine Receptor-selective Antagonists”,Neuropharmacology, 36 (9): 1157-1165.
Jorgensen, A. et al. (1985) “Synthesis of 7H-Pyrrolo[2,3-d]pyrimidin-4-amines”Liebigs. Ann. Chem., pp. 142-148.
Kaiser, S.M. and R.J. Quinn (1999) “Adenosine receptors as potential therapeutic targets”Drug Discovery Today4(12): 542-551.
Kiichiro, K. et al. “Synthesis of pyrazinecarboxylic acid derivs.—(II) derivs. of 3-aminopyrazinecarboxylic acid” (1961)Yakugaku Zasshi81: 1650-1653.
Lee T., et al., (1999) “Protective effects of renal ischemic preconditioning and adenosine pretreatment: role of A1 and A3 receptors”,72ndScientific Sessions of the American Heart Association, Atlanta, GA, p. 197.
Lee T., et al., (2000) “Protective effects of renal ischemic preconditioning and adenosine pretreatment: role A1 and A3 receptors”,Am. J. Physiol. Renal Physiol., 278: F380-F387.
Marx, D. et al. (2001) “Therapy of Bronchial Asthma with Adenosine Receptor Agonists or Antagonists”Drug News Perspect, 14(2): 89-100.
Mautner, H.G., (1961) “Potential Deoxyribonucleic Acid Cross-linking Agents. 8,8′-Bispurines”,J. Org. Chem.26(6):1914-1917.
Muller, C. E. et al. (1990) “7-Deaza-2-phenyladenines: Structure-Activity Relationships of Potent A1 Selective Adenosine Receptor Antagonists”J. Med. Chem., 33: 2822-2828.
Muller, C.E. et al. (1996) “Chiral Pyrrolo[2,3-d]pyrimidine and Pyrimido[4,5-b]indole Derivatives: Structure-Activity Relationships of Potent, Highly Stereoselective A1-Adenosine Receptor Antagonists”J. Med. Chem., 39:
Castelhano Arlindo L.
McKibben Bryan
Witter David J.
Cooper & Dunham LLP
OSI Pharmaceuticals, Inc.
Pryor Alton N
White John P.
LandOfFree
Compounds specific to adenosine A, receptors and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds specific to adenosine A, receptors and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds specific to adenosine A, receptors and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4123052